Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:57 PM
Ignite Modification Date:
2025-12-24 @ 7:57 PM
NCT ID:
NCT02899104
Eligibility Criteria:
Inclusion Criteria:
* Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC) per medical chart.
* Patients were at least 18 years of age as of the first diagnosis for mCRPC.
* Patients must have received at least one intravenous injection of Radium-223 (Xofigo).
* First injection of Radium-223 must have started between periods
1-January-2014 to 30-June-2014 or 15-November-2014 to present.
* Patients must have a minimum of 12 months documented follow-up records following last Radium-223 treatment or death within 12 months of last dose.
Exclusion Criteria:
* Patients who received Radium-223 as part in an interventional clinical trial
* Actively treated, or expect to be treated, in 6 months before last follow-up, for any other malignancy with the exception of non-metastatic skin cancer or low-grade superficial bladder cancer.
Healthy Volunteers:
False
Sex:
MALE
Minimum Age:
18 Years
Study:
NCT02899104
Study Brief:
Protocol Section:
NCT02899104